Antara Capital LP Revance Therapeutics, Inc. Call Options Transaction History

Antara Capital LP

5 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q4 2022 Feb 13, 2023	BUY	$18.32 - $30.66 $21.4 Million - $35.9 Million	1,170,200 Added 28.76%	5,239,600 $96.7 Million
Q3 2022 Nov 14, 2022	BUY	$14.33 - $28.47 $51 Million - $101 Million	3,560,100 Added 699.02%	4,069,400 $110 Million
Q2 2022 Aug 15, 2022	SELL	$11.52 - $20.4 $1.96 Million - $3.47 Million	-170,300 Reduced 25.06%	509,300 $7.04 Million
Q1 2022 May 16, 2022	BUY	$12.36 - $20.31 $5.93 Million - $9.74 Million	479,600 Added 239.8%	679,600 $13.3 Million
Q4 2021 Feb 14, 2022	BUY	$12.46 - $27.87 $2.49 Million - $5.57 Million	200,000 New	200,000 $3.26 Million

232

82.1M

680K

896K

Ticker RVNC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 82,305,696
Market Cap $212M
Description
Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials fo...

Get notified when there are updates to the investment portfolio of Antara Capital LP, based on Form 13F filings with the SEC.

Stay updated on Antara Capital LP with notifications on news.